The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies

In order to ascertain whether carboxyterminal pyridinoline cross-linked telopeptide of type I collagen (ICTP) might be useful as a serum screening parameter for bone metastases from non-prostate urological malignancies as well as prostate cancers, as series of 210 patients were examined. In addition...

Full description

Saved in:
Bibliographic Details
Published in:Cancer detection and prevention 2003, Vol.27 (1), p.14-18
Main Authors: Okamura, Takehiko, Akita, Hidetoshi, Tatsura, Hiroyuki, Kawai, Noriyasu, Nagata, Daisuke, Azemoto, Masataka, Iwase, Yutaka, Kohri, Kenjiro
Format: Article
Language:English
Subjects:
Aged
Alkaline Phosphatase - blood
Biomarkers, Tumor - blood
Bone metastasis
Bone Neoplasms - blood
Bone Neoplasms - secondary
Cancer
Cancer therapies
Collagen
Collagen - blood
Collagen Type I
Epidemiology
Humans
ICTP
Male
Middle Aged
Peptides - blood
Pharmaceutical industry
Prostate cancer
Prostate-Specific Antigen - blood
ROC Curve
Software
Urologic Neoplasms - pathology
Urological malignancy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In order to ascertain whether carboxyterminal pyridinoline cross-linked telopeptide of type I collagen (ICTP) might be useful as a serum screening parameter for bone metastases from non-prostate urological malignancies as well as prostate cancers, as series of 210 patients were examined. In addition to ICTP, serum alkaline phosphatase (ALP) and also prostate specific antigen (PSA) in the prostate cancer cases were assayed using commercial kits. The areas under the receiver operating characteristic (ROC) curves were 0.7846 for ICTP (cut-off point 9.6 μg/l), 0.8304 for ALP in prostate cancer cases, and 0.8278 for ICTP (cut-off point 10.6 μg/l), and 0.7139 for ALP in non-prostate cancer cases. While significance was only observed for ICTP and PSA in prostate cancer cases, borderline significance was also evident with ICTP for non-prostate malignancies, and with ALP for prostate cancer case. The results suggest that serum ICTP may be useful in combination with ALP as a quantitative clinical marker for low cost screening for bone metastases in patients with all types of urological malignancies.
ISSN:0361-090X
1877-7821
1873-443X
1877-783X
DOI:10.1016/S0361-090X(02)00172-1